Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05863234Phase 1Recruiting

Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Role: collaborator

NCT02828254Completed

A Follow-up Evaluation Study of PRI-724-1101

Role: lead

NCT02195440Phase 1Completed

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Role: lead

NCT00452205Unknown

Bone Marrow-derived Cells' Contribution to Tumor Formation and Inflammation

Role: lead

All 4 trials loaded